Impact of Genetic Mutations and Skin Rash on Colorectal Cancer Treatment
Author Information
Author(s): Saridaki Zacharenia, Tzardi Maria, Papadaki Chara, Sfakianaki Maria, Pega Fraga, Kalikaki Aristea, Tsakalaki Eleftheria, Trypaki Maria, Messaritakis Ippokratis, Stathopoulos Efstathios, Mavroudis Dimitris, Georgoulias Vassilis, Souglakos John
Primary Institution: University of Crete
Hypothesis
The study investigates the predictive significance of various genetic mutations and skin rash in metastatic colorectal cancer patients treated with cetuximab-based therapy.
Conclusion
KRAS and BRAF mutations, along with EREG expression, can serve as important biomarkers for selecting patients for anti-EGFR treatment in metastatic colorectal cancer.
Supporting Evidence
- Patients with KRAS mutations had significantly lower time to tumor progression and overall survival.
- BRAF mutations were associated with worse outcomes in metastatic colorectal cancer.
- EREG and AREG expression levels correlated with treatment response.
- Skin rash severity was linked to better treatment outcomes.
Takeaway
This study found that certain gene changes in cancer can help doctors decide which patients will benefit from a specific cancer treatment, and having a skin rash during treatment might also be a good sign.
Methodology
The study analyzed primary tumors from 112 metastatic colorectal cancer patients, assessing genetic mutations and skin toxicity during treatment.
Potential Biases
Potential biases may arise from the retrospective nature of the study and selection of patients.
Limitations
The study is retrospective and may not account for all variables affecting treatment outcomes.
Participant Demographics
The median age of participants was 66 years, with 60% male and 40% female.
Statistical Information
P-Value
p=0.001
Confidence Interval
95% CI 4.1–5.7
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website